Executive SummaryInternational Trade Commission grants Bristol-Myers Squibb temporary relief Jan. 10 following a recent federal circuit court determination that the company's disputed '657 patent is "likely to be sustained" ("The Pink Sheet" Dec. 18, T&G-4). The ITC issued a cease and desist order prohibiting domestic marketing of the antibiotic by Biocraft, Kalipharma and Purepac unless a bond is posted for 68% of the "entered value of the imported articles," ITC said in a notice published in the Jan. 18 Federal Register. The commission also gave a temporary limited exclusion order prohibiting foreign manufacturers from importing the product without posting bond for 68% of its value. The orders will remain effective until the ITC reaches its final determination, due March 15.
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.